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Objectives: Mechanical thrombectomy (MT) is not reimbursed by the Polish public health
system. We present a description of 5 years of experience with MT in acute stroke in
Comprehensive Stroke Centers (CSCs) in Poland.
Methods and results: We retrospectively analyzed the results of a structured questionnaire
from 23 out of 25 identiﬁed CSCs and 22 data sets that include 61 clinical, radiological and
outcome measures.
Results: Most of the CSCs (74%) were founded at University Hospitals and most (65.2%) work
round the clock. In 78.3% of them, the working teams are composed of neurologists and
neuro-radiologists. All CSCs perform CT and angio-CT before MT. In total 586 patients were
subjected to MT and data from 531 of them were analyzed. Mean time laps from stroke onset
to groin puncture was 250  99 min. 90.3% of the studied patients had MT within 6 h from
stroke onset; 59.3% of them were treated with IV rt-PA prior to MT; 15.1% had IA rt-PA during
MT and 4.7% – emergent stenting of a large vessel. M1 of MCA was occluded in 47.8% of cases.
The Solitaire device was used in 53% of cases. Successful recanalization (TICI2b–TICI3) was
achieved in 64.6% of cases and 53.4% of patients did not experience hemorrhagic transfor-
mation. Clinical improvement on discharge was noticed in 53.7% of cases, futile recanaliza-
tion – in 30.7%, mRS of 0–2 – in 31.4% and mRS of 6 in 22% of cases.
Conclusion: Our results can help harmonize standards for MT in Poland according to inter-
national guidelines.
© 2017 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Since 2016, mechanical thrombectomy (MT) with new genera-
tion devices is an approved reperfusion therapy for
acute ischemic stroke due to emergent large vessel occlusion* Corresponding author at: Department of Neurology, Jagiellonian Univ
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0028-3843/© 2017 Polish Neurological Society. Published by Elsevier S[1]. Intra-arterial stroke treatment, either pharmacological [2] or
mechanical [3,4], has been used for the last 20 years. The
introduction of new generation devices (stent retrievers), which
have been recognized as much more effective and safer than the
old generation tools (MERCI retriever) [5,6], was a signiﬁcant
milestone in intra-arterial stroke treatment. The efﬁcacy ofersity, Botaniczna 3, 31-503 Kraków, Poland. Tel.: +48 12 4248694;
p. z o.o. All rights reserved.
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IV rt-PA, where possible, was conﬁrmed in 2015 by ﬁve
prospective, randomized, open-label clinical trials: MR CLEAN
[7], ESCAPE [8], EXTEND-IA [9], SWIFT PRIME [10], REVASCAT [11].
Based on estimates from Catalonia, Spain, the number of
patients fulﬁlling inclusion criteria for MT averages 10:100 000
per year [12]. In Poland, with a population of 38.5 million, an
estimated number of as many as 3800 acute stroke patients
may fulﬁll criteria for MT each year.
According to the European Stroke Organization, in most
European countries the number of tertiary stroke hospitals
that provide MT on a 24/7 basis has grown signiﬁcantly in the
recent years [1]. Unfortunately, MT is not reimbursed by the
Polish public health care system (the National Health Fund).
Currently it is covered from the resources of the hospital where
it is performed. The number of Stroke Units in Poland is
sufﬁcient to deliver standard stroke care, however, there is no
formal network of the tertiary stroke centers in Poland.
Interestingly, we were able to identify 25 stroke centers, in
15 out of 16 voivodeships in Poland and all of these centers
fulﬁlled commonly accepted criteria for so-called tertiary
stroke centers [13], and were able to perform MT when needed.
In this paper we present an evaluation of the ﬁve years of
experience with MT treatment for acute ischemic stroke in
Poland. In brief, we review both the organizational proﬁle in
the 23/25 centers that submitted the completed questionnaire
and prospectively collected clinical databases of patients
treated with MT in 22/25 of these centers in the context of their
efﬁcacy and safety.
2. Methods
We identiﬁed 25 stroke centers that treated acute ischemic
stroke with MT with new generation devices between January
2012 and December 2016. Twenty-four centers agreed to
participate in our study. Twenty-two centers both completed
the structured questionnaire describing the procedures in the
center and delivered their patients' raw data. One center only
completed the structured questionnaire and provided infor-
mation about the number of treated patients without providing
further details (n = 5) and one did not ﬁll the questionnaire, only
providing information about the number of the treated patients
(n = 31). Four stroke centers were identiﬁed in one voivodeship,
three – in two voivodeships, two – in three voivodeships and
one in nine voivodeships. One voivodeship lacks such a center.
Finally, we reviewed 23 local protocols. Each protocol
included two common strategies for endovascular recanaliza-
tion in case of acute large vessel occlusion: MT proceeded by IV
rt-PA or primary MT in patients who had a contraindication to
IV thrombolysis or presented within 4.5–8 h after stroke onset.
The leader of each stroke center completed the structured
questionnaire, which allowed to determine differences be-
tween the centers with respect to center organization (work
time, composition of the team) and protocol (for example,
standard radiological procedures on admission and 24 h later,
inclusion for MT based on patient's consciousness status,
upper and lower National Institutes of Health Stroke Scale
NIHSS [14] limits, upper age limit for MT, interval between
stroke onset and groin puncture, interval between IV rt-PAadministration and decision about MT, preprocedural phar-
macotherapy, type of anesthesia during the procedure).
We gathered 22 different prospectively collected data sets.
To minimize bias related to different local speciﬁcities of these
data sets we reduced the number of analyzed parameters.
Finally, we limited the list to 61 variables that were available
from each center.
The following data were comprised on admission in each
patient. Demographics: age and gender; clinical data: stroke
etiology according to the Trial of Org10172 in acute Stroke
Treatment (TOAST) criteria [15], stroke risk factors (hyperten-
sion, ischemic heart disease, myocardial infarction, atrial
ﬁbrillation, diabetes mellitus), stroke severity on admission
assessed by the NIHSS [14]. Additionally, the following
procedure data were collected: initial brain vessel imaging
documenting site of large-vessel occlusion, time between
symptom onset and groin puncture, treatment with IV rt-PA
before MT, reasons for excluding patients from initial
treatment with IV rt-PA, treatment with IA rt-PA during MT
if needed, concomitant emergency stenting of large artery;
type of device: Solitaire stent retriever (Medtronic, MN, USA),
Penumbra aspiration system (Penumbra Inc., Alameda, CA,
USA), Trevo stent retriever (Stryker Neurovascular, Fremont,
CA, USA), ERIC (MicroVention Inc., Terumo), Catch (BALT
Company), Preset (Phenox GmbH), Aperio (Acandis GmbH), or
Revive – Codman Neuro (Johnson & Johnson).
Outcome data were divided into immediate (recanalization
rate and posttreatment hemorrhagic complications) and early
measures (stroke severity, neurological improvement, futile
recanalization, modiﬁed Rankin scale score on discharge and
in-hospital mortality) [16].
The recanalization results were assessed by digital sub-
traction angiography immediately after the procedure accord-
ing to Thrombolysis in Cerebral Infarction (TICI) criteria: grade
0 – no perfusion; grade 1 – penetration with minimal perfusion;
grade 2a – partial perfusion, <50%; 2b – partial reperfusion,
≥50–99%; grade 3 – no ﬂow constraint and complete perfusion
[17]. Successful reperfusion was deﬁned as TICI2b-3.
Posttreatment hemorrhagic complications were classiﬁed
according to the ECASS-1 classiﬁcation [18]. Hemorrhagic
infarction type 1 (HI1) was deﬁned as small petechiae along the
margins of the infarct and HI2 was deﬁned as conﬂuent
petechiae within the infarcted area but no space-occupying
effect. Parenchymal hematoma 1 (PH1) was deﬁned as blood
clots in ≤30% of the infarcted area with slight space-occupying
effect, and PH2 was deﬁned as blood clots in >30% of the
infarcted area with substantial space-occupying effect. Stroke
severity on discharge was assessed by the NIHSS.
Neurological improvement was deﬁned as decrease of >4
points on the NIHSS on discharge as compared to stroke onset
[19]. Disability on discharge was measured with the modiﬁed
Rankin Scale, mRS [16]. Good clinical outcome was deﬁned as a
mRS score of 0–2 on discharge.
Futile recanalization, i.e. the proportion of patients without
favorable outcome on discharge (neurological improvement of
>4 point on the NIHSS) despite successful recanalization was
also analyzed [20].
All-cause mortality on discharge was analyzed in all
centers. All CSCs had the local ethical committee's agreement
for performing MT in acute ischemic stroke.
Table 1 – Stroke center characteristics.
Characteristics N (%)
Patients eligible for thrombectomy
Only those who were able to sign informed consent 1 (4.3)
Only those who were able to sign informed consent
or who were able to conﬁrm their will in the
presence of two witnesses
3 (12.9)
All patients, including those with aphasia or
unconsciousness
19 (82.6)
Center organization
24/7 15 (65.2)
Only working hours 2 (8.6)
Only when the required personnel is available 6 (26.1)
Team composition
Neurologist plus interventional radiologist 18 (78.3)
Neurologist plus neurosurgeon 3 (12.9)
Neurologist plus vascular surgeon 1 (4.3)
Neurologist plus radiologist plus neurosurgeon 1 (4.3)
Neurologist plus cardiologist 1 (4.3)
Standard radiological admission procedures
Cranial computed tomography without contrast 23 (100)
Computed tomography with contrast 2 (8.6)
Angio-tomography, brain arteries 23 (100)
Angio-tomography, neck arteries 20 (87.1)
Perfusion tomography 1 (4.3)
Magnetic resonance 6 (25.1)
Routine radiological procedures after mechanical thrombectomy
Yes, routinely 24 h after the procedure 20 (87.1)
Yes, routinely 48 h after the procedure 3 (12.9)
No 0
Upper age limit for stroke patients eligible for mechanical thrombectomy
<80 years 6 (26.1)
<85 years 2 (8.6)
No age limit 15 (65.2)
Lower NIHSS limit for inclusion
>5 5 (21.7)
>7 2 (8.6)
>9 1 (4.3)
No limits 15 (65.2)
Interval between stroke onset and groin puncture
<6 h 3 (12.9)
6–8 h 14 (61.0)
>8 h accepted in special situations 6 (26.1)
Undetermined
Delay to assess IV rt-PA-induced recanalization before endovascular
treatment
30 min 10 (43.5)
30–60 min 8 (34.8)
>60 min 5 (21.7)
Pharmocotherapy immediately before MT
Aspirin 0
Aspirin plus heparin 0
Heparin 3 (12.9)
Non 20 (87.1)
Type of anesthesia
Local 12 (52.2)
General 11 (47.8)
Both 0
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Descriptive statistics included frequencies and percentage for
categorical data and means and standard deviations (SD) for
continuous variables. For some continuous variables, median
and interquartile ranges were also calculated. All statistical
analyses were performed using SAS 9.4 software.
3. Results
The 25 identiﬁed CSCs were established on the basis of stroke
units at university hospitals or neurological institutes [17],
state hospitals [2] or hospitals that had previously both
required radiological equipment and served as leading local
stroke centers. All CSCs had already had a neurovascular
intervention unit in their structure.
Nine of the CSCs performed less than 10 MTs, four centers
performed between 20 and 30 MTs, eight centers performed
between 30 and 40 MTs, and two carried out over 40 MTs each.
Fifteen out of the 23 CSCs included in the analysis (65.2%)
worked round the clock. Eighteen out of 23 teams (78.3%) were
composed of neurologists and neuroradiologists. All of the
CSCs performed computed tomography and angio-CT of brain
vessels before the MT procedure. Twenty CSCs (87.0%)
additionally performed angio-CT of the extracranial vessels.
After the MT procedure, all patients had a routine control CT
scan of the brain within 48 h after stroke onset. In 15 centers
(65.2%) there was no upper age limit for the procedure
established. An inclusion NIHSS score was speciﬁed in 8
centers (34.8% of the studied group). In 17 centers (73.9% of the
studied CSCs) the upper limit for the time lapse between stroke
onset and groin puncture was set at 8 h, in the remaining 6
centers (26.1% of the studied CSCs) – a longer time window was
accepted in special situations, like stroke located in the
vertebrobasilar region. In 18 centers (78.3% of the studied CSCs)
the interval between IV rt-PA administration and the decision
about implementing MT was not longer than 60 min. Only in 3
centers (13.0%) heparin was routinely used before the
procedure. Twelve centers (52.2%) accepted local anesthesia
and 11 – general anesthesia. Detailed information about the
centers' organization is shown in Table 1.
In total 586 patients were subjected to MT in the 25
identiﬁed centers. Raw data was obtained from 550 cases and
531 cases were ﬁnally included in the analyses, because they
had the minimum set of data (age, gender and mRS on
discharge). The baseline characteristics, including age, per-
centage of female patients, initial NIHSS score, stroke risk
factor proﬁle and stroke etiology of all patients included in the
analyses are shown in Table 2. Twenty-seven patients (5.1% of
the analyzed cases) were subjected to MT in 2012, 62 (11.7%) in
2013, 63 (11.9%) – in 2014, 111 (20.9%) – in 2015 and 268 (50.5%) –
in 2016.
Information on the time lapse between stroke onset and
the groin puncture was available in 504 patients (95% of
analyzed cases). Mean time lapse was 250  99 min (range: 60–
885 min). Four hundred ﬁfty-ﬁve (90.3%) patients had MT
performed within 6 h after stroke onset, 42 (8.3%) – within 6–
8 h, and 7 subjects (1.38%) had the procedure performed later
than 8 h from stroke onset.
Table 2 – Clinical characteristics and procedural para-
meters of all patients.
Characteristics
Age, y 66.6 (13.7)
Female gender, n (%) 273 (51.4)
NIHSS score on admission, median
IQR n = 523/531 (98.5)
16 (12–19)
(min: 0–max: 42)
Vascular risk factors
Hypertension, n (%) 338 (73.1)
Ischemic heart disease, n (%) 156 (29.4)
Myocardial infarction, n (%) 64 (12.1)
Atrial ﬁbrillation, n (%) 246 (46.3)
Diabetes mellitus, n (%) 140 (26.4)
Stroke etiology
Large vessel disease 124 (23.4)
Small vessel disease 0
Cardioembolic stroke 195 (36.7)
Not known 187 (35.2)
Rare 25 (4.7)
IV rt-PA status
IV rt-PA before mechanical thrombectomy 315 (59.3)
No IV rt-PA before mechanical thrombectomy
due to treatment window
64 (12.1)
No IV rt-PA before mechanical thrombectomy
due to VKA treatment
31 (5.8)
No IV rt-PA before mechanical thrombectomy
due to NOAC treatment
14 (2.6)
No IV rt-PA before mechanical thrombectomy
due to any antithrombotic treatment
18 (3.4)
Other reasons 89 (16.8)
Concomitant treatment procedures during thrombectomy
IA rt-PA during the procedure 80 (15.1)
Emergent stenting of extracranial arteries 25 (4.7)
Occlusion site
Carotid T occlusion, n (%) 85 (16.0)
M1 middle cerebral artery, n (%) 254 (47.8)
M2 middle cerebral artery, n (%) 65 (12.2)
M3 middle cerebral artery, n (%) 6 (1.1)
A1 anterior cerebral artery, n (%) 1 (0.2)
A2 anterior cerebral artery, n (%) 0
Vertebrobasilar arteries, n (%) 72 (13.6)
Multiple 46 (8.7)
Missing data 2 (0.4)
Type of thrombectomy device
Solitaire (Medtronic, MN, USA), n (%) 282 (53.1)
Penumbra (Penumbra, Alameda,
CA, USA), n (%)
76 (14.3)
CATCH (BALT), n (%) 42 (7.9)
Eric (MicroVention Inc., Terumo), n (%) 32 (6.0)
Preset (Phenox GmbH), n (%) 9 (1.7)
Aperio (Acandis GmbH), n (%) 8 (1.5)
Revive – Codman Neuro
(Johnson & Johnson), n (%)
6 (1.1)
Trevo (Stryker Neurovascular, CA, USA),
n (%)
4 (0.7)
Several, n (%) 26 (7.9)
Missing data, n (%) 46 (8.7)
Immediate outcome measures: TICI score
0, n (%) 79 (14.9)
1, n (%) 27 (5.1)
2a, n (%) 62 (11.7)
2b, n (%) 80 (15.1)
3, n (%) 262 (49.5)
Missing data, n (%) 21 (4.0)
Table 2 (Continued )
Characteristics
Immediate outcome measures: hemorrhagic transformation
No hemorrhagic transformation 284 (53.4)
HI1, n (%) 50 (9.4)
HI2, n (%) 34 (6.4)
PHI1, n (%) 43 (8.1)
PHI2, n (%) 38 (7.2)
Missing data, n (%) 82 (15.4)
Early outcome measures on discharge
NIHSS score on discharge, median IQR 6 (0–42)
Clinical improvement on discharge
(>4 points in NIHSS), n (%)
285 (53.7)
Modiﬁed Rankin Scale 0, n (%) 48 (9.0)
Modiﬁed Rankin Scale 1, n (%) 65 (12.2)
Modiﬁed Rankin Scale 2, n (%) 54 (10.2)
Modiﬁed Rankin Scale 3, n (%) 65 (12.2)
Modiﬁed Rankin Scale 4, n (%) 86 (16.2)
Modiﬁed Rankin Scale 5, n (%) 96 (18.1)
Modiﬁed Rankin Scale 6, n (%) 117 (22.0)
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IV rt-PA prior to the MT. Contraindications to IV rt-PA
administration before MT are listed in Table 2. Eighty patients
(15.1% of analyzed cases) had IA rt-PA administered during the
procedure and 25 patients (4.7% of analyzed cases) had
emergent stenting of a large vessel performed. Detailed sites
of vessel occlusion are listed in Table 2. In most patients (53%
of cases) MT was performed using the Solitaire device.
Successful recanalization (TICI2b and TICI3) was obtained in
322 patients (64.6%). Lack of hemorrhagic transformation on
the followed-up imaging check was found in 53.4% of patients.
The details are shown in Table 2.
117 patients (22% of cases) died during hospitalization. We
analyzed the individual mortality rate for the 13 out of the 22
centers which treated at least 10 cases. We found 4 centers
with a discharge mortality rate >25%; three with a mortality
rate between 20% and 25%, and 6 with a mortality rate <20%.
Clinical improvement was noticed in 285 cases (53.7% of
patients). Futile recanalization occurred in 30.7% of cases.
Good functional outcomes (mRS 0–2) on discharge were
achieved in 167 patients (31.4% of analyzed cases).
4. Discussion
In this paper we present a nationwide cohort of patients
treated with MT using new generation devices. This is an
analysis of real life experience, starting from 2012, a few years
before this therapy was universally approved [1]. Interestingly,
only 30% of all the studied patients were subjected to MT
before the publication of the milestone papers in 2015 [7–11]
and half of the patients – after the publication of the current
guidelines [1]. Since MT is currently not reimbursed in Poland
and access to this treatment is not common and varies from
region to region and not all CSCs performing MT participated
in the survey, the presented analysis does not provide
epidemiological data on this procedure in Poland.
However, we were able to summarize the detailed
organizational structure and diagnostic and treatment
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basis of existing well-recognized, experienced and well-
equipped stroke units remaining in close collaboration with
vascular intervention units. From the ﬁnancial point of view
this transformation was cost-free. Interestingly, in spite the
lack of central ﬁnancial support, most CSCs worked round the
clock. Labor cost and cost of devices for the MTs were covered
by the local hospitals.
All the included CSCs follow the consensus statement by
ESO-Karolinska Stroke Update 2014/2015 [1] in respect to the
fundamental requirements for treatment recommendations
for MT: introduction of treatment with MT only when there is a
contraindication for IV rt-PA or the therapeutic window for IV
rt-PA administration is prolonged (100%); team composition of
stroke neurologists and neuroradiologists or neurosurgeons
(96%); treatment decision issued by multidisciplinary team
(100%); expanded radiological work-up before MT (100%) or
employment of new generation devices for MT (100%).
It should be underlined that only in 3 of the studied CSCs
(13%) the accepted time lapse between stroke onset and groin
puncture equaled 6 h and 6 of the centers (26%) accepted a
longer time than 8 h in special situations. However, even if the
accepted therapeutic window was wider than 8 h, we found
that 90% of patients were treated still within the 6 ﬁrst hours,
as recommended in the current guidelines. Only 7 patients
(1.3%) were treated more than 8 h after stroke onset – ﬁve had
the thrombus located in the basilar artery and two had severe
stroke in the anterior circulation. It would be an important
improvement to harmonize the upper limit for MT in all
centers to the 6-h therapeutic window as it is recommended in
the present guidelines. According to recently published data
from a multicenter stroke registry in China comprising 632
patients who underwent endovascular treatment due to acute
middle cerebral artery occlusion, a time delay between stroke
onset and groin puncture greater than 270 min is associated
with risk of symptomatic intracranial hemorrhage (OR = 1.70,
95%, CI: 1.03–2.80) which, concomitantly, signiﬁcantly
increases 90-day mortality in these patients [21]. MT beyond
6 h may be reasonable only in special circumstances, including
basilar artery occlusion, where such treatment could result in
a high recanalization rate and favorable outcome [22].
Interestingly, in almost all centers (87%) no antithrombotic
treatment was used before or during the procedure. The
literature concerning periprocedural antithrombotic therapy
in MT is scarce [22]. However, in most of the studied stroke
centers, neither heparin, nor aspirin were used before MT,
especially if the procedure was preceded by IV rt-PA
administration [23]. Among the ﬁve milestone papers con-
cerning MT published in 2015, only the REVASCAT trial paper
stated that systemic anticoagulation was not allowed other
than in the form of heparinized saline infusion as per local
interventional procedure standards [11]. However, this pre-
caution did not result in an increase of intracerebral bleeding
complications as compared to the other four trials. On the
other hand, the protocol of the French cohort study evaluating
MT with the ERIC retrieval device in patients with acute
ischemic stroke allowed the use of an IV heparin bolus
administered at the beginning of the procedure in patients
without preceding IV rt-PA, which resulted in greater risk of
hemorrhagic transformation (12%) than in the previouslyreported studies (5–7%) [24]. The most recent ESO [1] and AHA/
ASA [25] guidelines do not give any practical clues to the issue
of periprocedural antithrombotic therapy in MT.
There is no preference as to the type of anesthesia during
MT in Poland. Meanwhile, in all the ﬁve milestone MT studies
published in 2015 [7–11] and according to most nationwide
registries, local sedation was used more frequently than
general anesthesia with intubation. Previous studies also
revealed that clinical outcomes and survival were signiﬁcantly
better in patients treated with local sedation in comparison to
subjects undergoing general anesthesia, because they did not
involve increased risk of symptomatic intracranial hemorrhage
[26,27]. The ESO guidelines cite the expert consensus statement
of the Society of Neurointerventional Surgery and the Neuro-
critical Care Society, which recommends using general anes-
thesia only in patients with severe agitation, low level of
consciousness (GCS < 8 pts), loss of airway protective reﬂexes
or respiratory compromise and in selected posterior circulation
stroke patients presenting with these features [28,29].
To improve patient selection according to published
recommendations [1], imaging of penumbra size should be
performed more commonly. So far, in the presented data only
one center performed perfusion CT routinely. What is more,
the patients' ASPECTS (Alberta Stroke Program Early CT score)
should be routinely evaluated to help the process of patient
selection. Nearly all previous studies and nationwide registries
used ASPECTS scores in the qualifying process for MT and their
practical implementation has been lately recommended in the
ESO [1] and AHA/ASA [25] guidelines.
According to the current guidelines, older age is not a
reason to withhold MT for adjunctive treatment. We found,
however, that that 8 out of 23 centers (23%) still used an upper
age limit for patient selection. It cannot be excluded that the
reason for that is limited access to the procedure in Poland,
therefore younger patients with stroke are the ones who are
qualiﬁed with preference for MT.
Even though our study does not provide epidemiological
data on MT in Poland, it can be noted that our patients showed
similar demographics, stroke risk factor proﬁles and stroke
etiology as the groups described in previously published
clinical trials and real-life data studies. Moreover, the number
of patients treated with IV rtPA before the procedure (59.3%)
was also similar to that in most previous studies, in which it
varied from 46% to 68% of all studied patients. In two clinical
trials, MRCLEAN [7] and ESCAPE [8], the percentage of patients
treated with IV rt-PA before MT was higher than in our cohort
and equaled 87% and 73% of all studied patients, respectively,
whereas in two other studies, EXTEND [9] and SWIFT [10], due
to characteristics of the protocol, intravenous thrombolysis
preceded MT in all cases.
It is important to underline that 63 of the analyzed patients
underwent MT due to the fact that they were under the
inﬂuence of antithrombotics used to treat concomitant atrial
ﬁbrillation. MT is the only available causative treatment for
this subgroup of patients. There is little data on this topic in the
literature. In a recent study, MT in patients receiving antic-
oagulants achieved similar efﬁcacy as in those without a
previous history of antithrombotic intake. There was, howev-
er, a non-signiﬁcant trend toward greater incidence of
symptomatic intracranial hemorrhage and lower mortality
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possible explanation of this ﬁnding was that clots due to
cardioembolic stroke could be removed more easily than the
atherothrombotic ones [30].
In the current study we were able to compare only
immediate and early outcome measures to those published
in the literature. Successful recanalization deﬁned as a TICI
score of 2b or 3 was achieved in 64.6% of cases. Most previous
MT trials showed higher successful recanalization rates,
reaching from 72% to 88% [7–11]. On the other hand, the
median NIHSS score on discharge (6 points) was similar to that
reported in previous studies 24 h after the procedure (4–6
points) [8,31]. Moreover, the percentage of patients that
improved by 4 or more points in the NIHSS on discharge was
similar to that recorded in a Swedish cohort (58.6% vs. 63%) [32].
Unfortunately, in-hospital mortality in the presented case
series was high (22%). This result does not seem to be related to
the initial neurological deﬁcit, since the median NIHSS score on
admission was comparable to that previously reported in
clinical studies and case series. We analyzed in detail the
possible reasons for a high (>25%) in-hospital mortality in four
of the studied centers. We found that one of them had included
patients with signiﬁcantly more severe neurological deﬁcits on
admission (median NIHSS: 18) as well as signiﬁcantly more
patients with vertebrobasilar thrombus location (26% of all
treated patients) as compared to others. Another one of these
four centers also included a higher percentage of patients with
thrombus located in vertebrobasilar arteries (22.7%). The third
center's data comprised cases with signiﬁcantly more severe
neurological deﬁcits on admission. Interestingly, the fourth of
these centers – which had a 36.4% in-hospital mortality rate –
had a signiﬁcantly longer average time from stroke onset to
groin puncture as compared to other included centers (330 min,
IQR: 240–390 vs 240 min, IQR: 180–300; p < 0.05).
Unfortunately, only two centers systematically collected
90-day outcome data (in total = 178), thus, we were not able to
show this valuable information for all included patients. In the
ﬁrst center in-hospital mortality was 18.3% and 90-day
mortality – 21.2%, in the second center – 23% and 28.4%,
respectively. The rate of 90-day mortality seems comparable to
that previously reported in other national MT registries from
Austria and Brazil (20.9% and 23%, respectively) [33,34].
A limitation of the presented study is the inclusion of
retrospectively collected patient data drawn from 23 different
protocols. What is more, the collected data were not veriﬁed
centrally, which could bias the results.
5. Summary/conclusion
Our study allowed to describe a cross country real-life
experience in treatment of acute stroke with MT and
highlighted the pros and cons of the used protocols. These
results can help harmonize standards of care in acute ischemic
stroke patients in Poland according to available guidelines.
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